BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250508T190000
DTEND;TZID=Africa/Nairobi:20250508T203000
DTSTAMP:20260522T041041
CREATED:20250414T200448Z
LAST-MODIFIED:20250622T144009Z
UID:24388-1746730800-1746736200@kesho-kenya.org
SUMMARY:Management of Indolent Lymphomas
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof Nicholas Otieno Abinya \nSpeakers & Topics: \n\nDr Samson Mutanda: Practical Approaches in Clinical Case‑Driven Exploration\nProf Shahin Sayed: Histopathology & Low‑Grade Lymphomas\nDr Matilda Ongondi: CT Treatment Algorithm – A Practical Approach\n\nDr. Samson Mutanda – presented case-based exploration of CLL management in Kenyan settings.\n– Key clinical points:\n• CLL is heterogeneous and often indolent; many patients start with watchful waiting.\n• Symptomatic cytopenias and disease progression warrant treatment.\n• Therapy included bendamustine\, rituximab\, venetoclax\, and novel agents like ibrutinib.\n– Highlighted diagnostic limitations due to access to FISH\, molecular testing\, and cost of targeted therapies.\n– Underscored importance of tailored care\, especially in young patients and those with co-morbidities. \nDr. Matilda Ongondi – Provided a clinical introduction to indolent lymphomas\, which are slow-growing B-cell neoplasms such as CLL/SLL\, follicular lymphoma\, and MZL.\n– Emphasized the necessity for clinical vigilance and long-term monitoring.\n– Stressed the need for diagnostic precision\, the role of immunophenotyping\, and the heterogeneity of clinical presentations.\n– Highlighted treatment considerations: watchful waiting\, targeted therapy\, and challenges in resource-limited settings. \nProf. Shahin Sayed – Reviewed WHO-HEM5 classification of indolent lymphomas\, emphasizing pathology-driven subtypes.\n– Covered key immunophenotypic markers: CD5\, CD23\, LEF1\, BCL2\, Cyclin D1\, etc.\n– Presented rare pediatric and adolescent cases\, illustrating diagnostic complexity and variability.\n– Detailed histologic signs of aggressive transformation (e.g. high Ki-67\, prolymphocytic features).\n– Outlined molecular diagnostics: del(11q\, 13q\, 17p)\, TP53 mutations\, IGHV SHM – all important for prognosis and treatment.\n– Discussed evolving terminology: classic FL\, follicular lymphoma with uncommon features (uFL)\, and follicular large cell lymphoma.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-indolent-lymphomas/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250505-WA0000-e1746479789592.jpg
END:VEVENT
END:VCALENDAR